Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab....

Descripción completa

Detalles Bibliográficos
Autores principales: Yonezawa, Toshiyuki, Suzuki, Atsushi, Fukumitsu, Kensuke, Katano, Takuma, Kako, Hisashi, Ishii, Makoto, Niimi, Akio, Imaizumi, Kazuyoshi, Sakamoto, Koji, Omote, Norihito, Yamaguchi, Etsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125217/
https://www.ncbi.nlm.nih.gov/pubmed/37124053
http://dx.doi.org/10.1016/j.rmcr.2023.101857
Descripción
Sumario:We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.

Ejemplares similares